Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pancreatic cancer diagnosis by free and exosomal miRNA
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858795/
CigsNWhiskey- see Phillife's post #4583.
Delving Into Brain Injuries With the N.F.L.’s Money - NYTimes.com
http://mobile.nytimes.com/2013/12/17/sports/football/agency-selects-brain-trauma-projects-for-nfl-grant.html
HEPATITIS C TREATMENT, SOVALDI, APPROVED BY FDA: LESS INVASIVE, MORE EXPENSIVE
http://www.bustle.com/articles/10321-hepatitis-c-treatment-sovaldi-approved-by-fda-less-invasive-more-expensive
Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi
http://www.fiercepharma.com/story/activists-pounce-1000-day-price-gileads-hep-c-wonder-drug-sovaldi/2013-12-09
Obama pledges up to $5 billion for global AIDS fund
http://www.usatoday.com/story/news/politics/2013/12/02/obama-world-aids-day-2013/3804569/
Mixed Martial Arts: A Massive Lawsuit Waiting to Happen?
http://finance.yahoo.com/blogs/daily-ticker/mixed-martial-arts-massive-lawsuit-waiting-happen-150400110.html
Philife,
I was wondering why Dr. T wants the brain injury test to be "more specific " as opposed to more sensitive. I realized that it does make sense for sports, because if you can get quick results and the test is negative, the player can be on the field again and not miss the rest of the game. Again, depends on how quick is the test and how specific.
At the opening, did anyone mention about the patent AEMD holds for exosomes. It seems like a very broad patent - seems like it comes into play every time exosomes are removed from the body! If true, that by itself can be a huge revenue source for the company.
philife,
Thank you. You have removed a major point of confusion and thus doubt about this aspect of AEMD from my mind.
I have always had this question about the assays - are these are exosomal assays? The issue is that there are so many new assays in the market for the same oncology conditions which are mentioned at various times in the AEMD PRs that one wonders what shall be the advantage of the assays offered by AEMD.
Also, why a new assay in the saturated field of HIV? This is just a straight question. A few years back there was a PR from AEMD about research with Morehouse School of Medicine about NEF proteins being transported in exosomes - any update?
philife,
Thank you very much for your efforts.
Reading thru your post makes me wonder if there may be an application for the brain test for other contact sports like boxing, hockey, mixed martial arts, etc., Another possible application can be ambulances or ER's.
Also, considering that brain injuries are the hot topic in the NFL, a possible idea can be to get a baseline test from a player before a NFL game. This way if the test is redone after a possible concussion, it can be determined if the injury is recent or new…Just a thought, not knowing the practical aspects and the cost issues.
From yesterday's Form 10-Q for CYTOSORBENTS CORP
"In August 2012, the Company was awarded a $3.8 million contract by the Defense Advanced Research Projects Agency (DARPA) for its "Dialysis-Like Therapeutics" program to treat sepsis. This five-year contract is for advanced technology development of our hemocompatible porous polymer technologies to remove cytokines and a number of pathogen and biowarfare toxins from blood. CytoSorbents has begun work on Year 2 milestones and is currently working with the recently announced systems integrator, Battelle Laboratories, and its subcontractor NxStage Medical, who are responsible for integrating the technology developed by CytoSorbents and others into a final medical device design prototype, and evaluating this device in septic animals and eventually in human clinical trials in sepsis. CytoSorbents' work is supported by DARPA and SSC Pacific under Contract No. N66001-12-C-4199."
MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer
http://onlinelibrary.wiley.com/doi/10.1002/cncr.28254/abstract
From yesterday'S PR -
"As a result of crossing the IDE approval threshold, we opened the door to advance relationships with medical institutes that have clinical interest in expanding Hemopurifier® indications to include various forms of cancer."
"When we initiated our first cancer research activities, we were making two intuitive yet forward-looking bets. The first was that exosomes would emerge to become a vital therapeutic target. The second was a belief that novel immunotherapies would rethink the landscape for treating cancer. Today, tumor-secreted exosomes are well-documented therapeutic targets and cancer immunotherapies are expected to take center stage in the cancer treatment arena. There is growing hope that the marriage of traditional cancer therapies with next-generation immunotherapies may someday allow cancer to become a manageable condition much like HIV-infection is managed through a cocktail of treatment mechanisms. At Aethlon Medical, our role is to provide the oncology community with a therapeutic tool that counters the immunosuppressive impact of exosomes without adding drug toxicity to companion cancer therapies."'
"Extracorporeal Removal of Microvesicular Particles" -from Oct, 2012. With all the tremendous research in the field of cancer being directed towards exosomes, one wonders what is the worth of this patent by itself?
http://www.prnewswire.com/news-releases/aethlon-medical-announces-issuance-of-cancer-therapy-patent-175781691.html
"The patent entitled "Extracorporeal Removal of Microvesicular Particles," provides Aethlon Medical the exclusive right to remove immune suppressive microvesicular particles, which include but are not limited to exosomes from the circulation of treated patients. A therapy able to inhibit or reduce the presence of cancer-secreted exosomes would address a significant unmet medical need in the effort to combat cancer."
Link for Editorial in the Journal -
http://www.intechopen.com/journals/exosomesandmicrovesicles/editorial-8-april-2013
Exosomes and Microvesicles (you have to click on the journal to see the topics - Dr. Taylor is one of the Editors-in-chief )
http://www.asemv.org/about-evs.html
Key statement - (I am assuming that this indicates exosome studies in the future.)
"The approval of our IDE has also unlocked the ability to advance clinical partnering programs with medical institutes that are pursuing indications of our Hemopurifier® in cancer care."
The Worldwide Market Landscape for Exosomes: Research and Translational Opportunities
Molecular Medicine Congress 2013
http://www.labtube.tv/channel.aspx?v=157707&u=Molecular%20Medicine%20Congress%202013
Detection and Clinical Implications of Circulating Tumor Cells in Cancer Patients
Molecular Medicine Congress 2013 ( Very technical - but does give an idea about the importance of CTCs in cancer management and thus how well AEMD is placed in this field.)
http://www.labtube.tv/channel.aspx?v=157705&u=Molecular%20Medicine%20Congress%202013
Clinical Relevance of CTCs in Primary and Metastatic Breast Cancer
Molecular Medicine Congress 2013
http://www.labtube.tv/channel.aspx?v=157716&u=Molecular%20Medicine%20Congress%202013
http://www.cellr4.org/article/412
Dr. Taylor mentioned.
Zone in with Zon”—Exosomes: Tiny Packets of RNAs with Major Significance and Potential
http://www.bioquicknews.com/node/1347
" NIH has recently announced its intention to award $17 million to fund 24 new research projects to understand how exosomal RNA is involved in communication between cells and how these RNAs may be used as biomarkers for diseases."
Tumor-derived exosomes and microvesicles in head and neck cancer: Implications for tumor biology and biomarker discovery
http://onlinelibrary.wiley.com/doi/10.1002/pmic.201200533/abstract
"It has therefore been suggested that HNC-derived vesicles could represent a useful source for biomarker discovery, enriched in tumor antigens and cargo; hence fundamentally important for cancer progression. "
Exosomes and Microvesicles in the Circulation
http://www.labtube.tv/channel.aspx?v=157714&u=Molecular%20Medicine%20Congress%202013
Exosomes and Microvesicles in the Circulation
http://www.labtube.tv/channel.aspx?v=157714&u=Molecular%20Medicine%20Congress%202013
Towards an Exosomes-based Molecular Test for Remission Monitoring of Cancer
http://www.labtube.tv/channel.aspx?v=157711&u=Molecular%20Medicine%20Congress%202013
The fundamentals certainly do not look good. However my perspective is that this is a game changing technology from several fronts :
HCV - AEMD is planning studies with Fresenius. This can be a win win for both. Can be a huge revenue booster for F as they already are dealing with a lot of people with HCV. They have the infrastructure in place to get this going if it works out.
I feel that health care companies, insurance companies and the govt.(remember that the HP is already validated by DARPA) may take interest in this if they are made to realize the potential in terms of savings. HP as an adjunct to anti-HCV meds would decrease the total cost and hopefully give better long term results.
Sepsis - As we know this seems to be a multi - billion dollar market with no real cure in sight. The fact that AEMD was chosen by DARPA, and we are working with Batelle speaks a lot for HP.
It is amazing for a penny stock company to be partnering with some of the leading institutions around (I forgot about possible studies regarding exosomes with M.D. Anderson in Texas!).
There are other applications for the HP, which may add to the bottom line if any of the above take off.
High Price of Cancer Drugs 'One of Biggest Issues in Healthcare'
http://www.medscape.com/viewarticle/804655?src=wnl_edit_specol&uac=18396FN
The Pharmaceutical Strategy Conference
http://www.elsevierbi.com/mkt/Conf/PSA/2013
Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C (Increased liver enzymes with high dose - Hopefully awareness of the HP becomes widespread enough that companies start thinking of using it in studies for new drugs. Possibly low dose required for drugs because of low initial viral load, more efficacy for the drug for the same reason, shorter duration i.e fewer weeks for drugs to be administered, more economical ....)
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=780456
Global policy report on the prevention and control of viral hepatitis
http://www.who.int/csr/disease/hepatitis/global_report/en/index.html
HCV treatment in children and young adults with HIV/HCV co-infection in Europe
"Conclusions: There is a very limited experience of treating HCV in HIV/HCV co-infected children. Our results show poor treatment outcomes in these cases, most of whom had advanced fibrosis and GT1."
http://pag.ias2013.org/abstracts.aspx?aid=2044